

**MARK T. MURPHY, MB**

Department of Cardiology, Cleveland Clinic;
Member, Royal College of Physicians of Ireland.

BRUCE L. WILKOFF, MD

Director, Cardiac Pacing and Tachyarrhythmia
Devices, Department of Cardiology, Cleveland
Clinic.

What internists should know about amiodarone

AMIODARONE'S POPULARITY has waxed and waned since it was originally introduced in the 1960s as an anti-ischemic drug,¹ and approved by the FDA in 1985 as an antiarrhythmic. It is the most effective antiarrhythmic drug available, and is now used almost exclusively for this purpose, even though it has gained some notoriety for toxicity.

We believe it will play an increasingly important role in the treatment of many arrhythmias, given its neutral effects on inotropy and low incidence of associated proarrhythmia.² Furthermore, it has unique safety in the setting of coronary disease and left ventricular dysfunction.

■ INDICATIONS

Although the only approved indication for amiodarone is the treatment of life-threatening arrhythmias unresponsive to adequate doses of other available antiarrhythmics, there is substantial data on its use in other populations. In this review, we propose a practical approach for follow-up of patients on long-term amiodarone therapy, and for use of amiodarone in four clinical categories:

- Atrial fibrillation.
- After myocardial infarction (MI).
- Primary prevention of sudden cardiac death.
- Secondary prevention of sudden cardiac death.

■ ANTI-ARRHYTHMIC EFFECTS

Amiodarone suppresses and prevents cardiac arrhythmias by directly prolonging the duration of the action potential—the “electrocardiogram” of each cardiac cell—and the repo-

■ ABSTRACT

Amiodarone is a potent and versatile antiarrhythmic. Despite side effects involving the lungs, heart, thyroid, and other organs, it is effective in the treatment of refractory atrial and ventricular arrhythmias and it has unique safety in patients with coronary disease and left ventricular dysfunction. This review discusses the evolving indications for amiodarone and management of toxicities and drug interactions.

■ KEY POINTS

Amiodarone therapy reduces the frequency of shocks from implantable defibrillators by improving control of atrial and ventricular arrhythmias.

Current data do not support routine use of amiodarone after myocardial infarction, even in high-risk patients. The population likely to benefit most from amiodarone has yet to be defined, but will probably include some patients who receive implantable cardioverter-defibrillators after myocardial infarction.

Pulmonary toxicity related to amiodarone is usually reversible by stopping the drug. High-dose corticosteroids may hasten resolution of lung injury.

Amiodarone increases the effect of warfarin and digoxin. Because of its beta-blocking activity, it potentiates the effect of other beta-blockers and may slow atrioventricular nodal conduction when used with some calcium-channel blockers.

larization time, and it does this mainly by blocking cellular potassium channels. While its essential mode of action is uncertain, homogenous lengthening of repolarization likely contributes to its antiarrhythmic activity. Amiodarone also depresses sinus and atrioventricular node automaticity, ie, the ability to initiate electrical impulses without an external stimulus. In addition, amiodarone has some beta-adrenergic, alpha-adrenergic, calcium-channel blocking, and sodium-channel blocking activity.³

■ PHARMACOKINETIC PROFILE

Amiodarone is an iodine-rich benzofuran derivative that is eliminated primarily by hepatic metabolism and biliary excretion. Because of first-pass metabolism in the liver and the intestinal mucosa and incomplete absorption, only 35% to 65% of an oral dose is bioavailable. Amiodarone has a high volume of distribution⁴: concentrations in the myocardium are 10 to 50 times those in plasma.⁵ Because it has such an affinity for adipose tissue, an estimated 10 to 15 g of the drug are necessary to saturate these stores.³ Once the steady state has been reached, the elimination half-life is long and variable, ranging from 16 to 180 days (mean, 52 days).⁶

In clinical practice, these characteristics mean that:

- Loading doses are necessary.
- The anti-arrhythmic effect is delayed.
- The elimination phase is protracted once the drug has been discontinued.
- There will usually be no serious consequences if the patient misses a dose or two by mistake.

Its major metabolite is desethylamiodarone, which is pharmacologically active. Interestingly, the iodide concentrated in the liver during amiodarone metabolism acts like radiographic contrast, increasing the radiographic density of the liver on computed tomography.

■ AMIODARONE FOR ATRIAL FIBRILLATION

Amiodarone is effective in treating a wide range of atrial arrhythmias. However, radiofrequency ablation has superseded drug therapy

for atrioventricular (AV) nodal and bypass tract tachyarrhythmias, such as Wolff-Parkinson-White syndrome. Amiodarone is of greatest clinical use in atrial fibrillation and atrial flutter. Moreover, amiodarone is clearly effective in patients with arrhythmias refractory to conventional agents.⁷

As part of medical therapy for atrial fibrillation, amiodarone may:

- Slow the ventricular response, due to its AV nodal blocking activity.
- Convert the rhythm to sinus rhythm.
- Maintain sinus rhythm after cardioversion.

The dose generally required for controlling atrial fibrillation is lower than that required for controlling ventricular arrhythmias, with less consequent toxicity.⁸ Recently, amiodarone has shown some promise in the prevention of atrial fibrillation following cardiac surgery.⁹

■ AMIODARONE AFTER MYOCARDIAL INFARCTION

It became clear by the mid-1970s that frequent ventricular ectopic beats and depressed left ventricular function after MI predicted increased mortality.¹⁰ An intensive search began for an antiarrhythmic to suppress ventricular ectopic beats and thereby improve prognosis. Data from the Cardiac Arrhythmia Suppression Trial (CAST) indicated that flecainide, encainide, and moricizine were proarrhythmic and actually increased sudden death after MI, thus precluding their use in coronary disease.^{11,12}

Early reports, such as the Basel Antiarrhythmic Study of Infarct Size (BASIS),¹³ suggested that amiodarone could significantly reduce arrhythmic events and total mortality after MI. In this study of 312 post-MI patients, mortality was reduced by 61% ($P < .05$) in patients receiving amiodarone, compared with those receiving placebo.

In the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT),¹⁴ survivors of MI with repetitive ventricular premature depolarizations were treated with either amiodarone or placebo. In the European Myocardial Infarct Amiodarone

The dose for atrial fibrillation is lower than for ventricular arrhythmia

Trial (EMIAT),¹⁵ survivors of MI with depressed left ventricular function received amiodarone or placebo. In EMIAT, the rate of mortality from all causes did not differ between the two groups, but there were 35% fewer ($P = .05$) deaths due to arrhythmia in the treated group. In CAMIAT, deaths due to arrhythmia were reduced by 48.5% ($P = .016$), with a trend towards a reduction in all-cause mortality.

Conclusions about optimal use of amiodarone after MI

While the CAMIAT and EMIAT results are less striking than the earlier BASIS results, they confirm that amiodarone has a low incidence of proarrhythmia and is safe to use in patients with left ventricular dysfunction. However, the results do not support the routine use of amiodarone after MI, even in high-risk patients. The population likely to benefit most has yet to be defined, but it will likely include some patients who receive implantable cardioverter-defibrillators.

■ PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH

Amiodarone has been studied in a number of large trials in the primary prevention of sudden cardiac death.

The markers of increased risk of sudden cardiac death include:

- Left ventricular dysfunction.
- Frequent or complex ventricular ectopic beats.
- Nonsustained ventricular tachycardia.

The *Grupo de Estudio de la Sobrevida en la Insuficiencia Cardíaca en Argentina* (GESICA) trial,¹⁶ which randomized 516 heart failure patients to amiodarone or standard treatment, was stopped early because of a 27% ($P = .16$) risk reduction in sudden death in the amiodarone group, which generated considerable excitement at the time. However, this early optimism was offset by the results of the more recent Veterans Affairs Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure (CHF STAT),¹⁷ which studied a similar patient population and found no survival benefit in the amiodarone group. These disparate results can perhaps be explained by the

larger number of patients in the GESICA trial with nonischemic dilated cardiomyopathy, a subgroup in which amiodarone may be more effective in preventing sudden cardiac death.¹⁸

These results leave us ambiguous about amiodarone's role as monotherapy in the primary prevention of sudden cardiac death. The Multicenter Automatic Defibrillator Implantation Trial (MADIT)¹⁹ attempted to resolve this ambiguity by randomizing patients to undergo conventional therapy—usually amiodarone—or implantation of a cardioverter-defibrillator. To be included in this trial, patients had to have coronary disease, nonsustained ventricular tachycardia, an ejection fraction of 35% or less, and ventricular tachycardia induced at electrophysiology study. The all-cause survival rate at 5 years was 61% in patients receiving medical therapy, vs 84% in patients with an implantable cardioverter-defibrillator ($P = .009$).

Other trials of implantable cardioverter-defibrillators as primary prevention are underway. Combination therapy with an implantable cardioverter-defibrillator plus amiodarone is now commonplace; the rationale is to limit shocks due to fast atrial fibrillation and frequently recurring ventricular arrhythmias.

In short, the patient at high risk of sudden cardiac death (eg, the MADIT population) is best served by an implantable cardioverter-defibrillator. Although in the future a survival benefit may be demonstrated in certain patient subgroups, such as those with non-ischemic dilated cardiomyopathy, amiodarone's greatest use is currently in the control of symptoms related to ventricular arrhythmias.

■ SECONDARY PREVENTION OF SUDDEN CARDIAC DEATH

Amiodarone is effective in preventing and terminating refractory ventricular arrhythmias.²⁰ Before the advent of the implantable cardioverter-defibrillator, amiodarone was the only treatment for arrhythmias refractory to conventional therapy. The Cardiac Arrest in Seattle: Conventional Versus Amiodarone

The patient at high risk of sudden cardiac death is best served by an implantable defibrillator

TABLE 1

Incidence of amiodarone-induced side effects

SYSTEM AND SIDE EFFECTS	INCIDENCE
Cardiac	
Sinus bradycardia*	0% to 10%
Torsades de pointes	<1%
Pulmonary	
Pneumonitis†	5% to 7%
Asthma exacerbation	Not available
Cough	Not available
Thyroid	
Hypothyroidism	<3%
Hyperthyroidism	<2%
Gastrointestinal	
Nausea/vomiting*	Common
Constipation*	Common
Mild transaminase elevation	15% to 20%
Alkaline phosphatase elevation	Uncommon
Hepatitis	Rare
Neurologic	
Fatigue	1% to 16%
Ataxia	4% to 24%
Headaches*	
Neuropathy	6% to 10%
Sleep disturbance	Not available
Myositis	Rare
Ocular	
Corneal microdeposits	Common
Macular degeneration	Rare
Optic neuritis	Rare
Renal	
Elevated creatinine	Rare
Dermatologic	
Photosensitivity†	Common
Blue-grey skin discoloration	1% to 7%
Pruritic rash	Infrequent
Miscellaneous	
Hyperglycemia	Rare
Mild elevation of lipids	Common
Anemia	Rare
Thrombocytopenia	Rare
Epididymitis	Rare

*Dose-related

†Partially dose-related

Drug Evaluation (CASCADE) study,²¹ which randomized cardiac arrest survivors to empiric amiodarone vs conventional therapy, demonstrated favorable results for amiodarone: survival at 6 years was 58% in the amiodarone group and 37% in the group treated conventionally. The recently reported Anti-arrhythmics Versus Implantable Defibrillator (AVID) trial²² randomized 509 patients with symptomatic ventricular arrhythmias to antiarrhythmic drug therapy, primarily amiodarone, and 507 patients to implantation of a cardioverter-defibrillator. Survival at 3 years was 75% in the group that received an implantable cardioverter-defibrillator and 64% in the drug therapy group. Interestingly, after 24 months, about 20% of patients had either crossed over to or added the alternative treatment, suggesting the complimentary nature of both therapies.

Still ongoing are the Canadian Implantable Defibrillator Study (CIDS) and Cardiac Arrest Study Hamburg (CASH), which will further elucidate the roles of amiodarone and the implantable cardioverter-defibrillator in treating and preventing the recurrence of life-threatening arrhythmias.

Currently, in patients at risk for a second sudden cardiac death event or serious destabilizing ventricular arrhythmias (hypotension, syncope), therapy with an implantable cardioverter-defibrillator is preferred. Amiodarone monotherapy is acceptable if a device is contraindicated, for whatever reason.

TOXICITY

Although amiodarone has serious toxicities which involve, primarily, the lung, heart, liver, or thyroid gland, and which raise the threshold for its use, these toxicities can be managed effectively to take advantage of its unique antiarrhythmic properties (TABLE 1). (Notably, in the AVID trial,²² 85% of the amiodarone-treated patients continued to take the drug 2 years after the trial began.) Side effects can be minimized by using lower doses or, sometimes, by reducing the daily dosage if symptoms occur. Regular monitoring of a variety of body systems is useful in preventing and managing amiodarone-induced side effects (TABLE 2).

**Amiodarone's
elimination
half-life is
long and
variable**

Pulmonary effects

Amiodarone-induced pulmonary toxicity is a much-feared complication of amiodarone therapy. Chest x-ray is the primary surveillance test, and radiographic changes are typically bilateral and diffuse with a combination of interstitial infiltrates (FIGURE 1). A reasonable estimate of the incidence is 5% to 7% of patients receiving amiodarone, 5% to 10% of whom may die.²³ Amiodarone-induced pulmonary toxicity seems more common in patients receiving a higher maintenance dose, in patients of advanced age, and in those with a lower pretreatment hemoglobin-corrected diffusing capacity (DLCO).²⁴

Nonspecific symptoms of dyspnea, cough, and chest pain are typical, and the patient may be febrile, with rales or a pleural rub. Exacerbation of asthma occurs only rarely.

Toxicity has been defined as two of the following:

- New or worsening symptoms.
- A new lung abnormality or worsening of infiltrates on chest roentgenogram.
- A decline of at least 15% in either the total lung capacity or the DLCO.

Gallium scanning of the lungs may help distinguish amiodarone-induced pneumonitis from congestive heart failure or pulmonary embolism. Baseline pulmonary function tests with DLCO and chest roentgenography are recommended, with periodic retesting based on symptoms. A chest roentgenogram should be obtained every 4 to 6 months. Withdrawal of the drug must be balanced against the risk of arrhythmia recurrence. There is no single laboratory test or clinical parameter that unequivocally establishes the diagnosis of amiodarone-related pulmonary toxicity. Diagnosis requires the exclusion of occult heart failure, infection, and other possibilities, such as pulmonary embolism, together with a reasonable collection of symptoms or findings. Occasionally, when amiodarone is the best or the only therapy available, one can consider reinstituting therapy at a lower dose.

Cardiac effects

Amiodarone prolongs the action potential duration and the refractory period of myocardial cells and therefore prolongs the QT interval. Nevertheless, the incidence of amio-

TABLE 2

Recommended monitoring during amiodarone therapy

TEST	INTERVAL
Laboratory tests	Baseline, as symptoms occur, and every 4 to 6 months
Renal function	
Complete blood count	
Liver function	
Thyroid function	
Electrocardiogram	Baseline, as symptoms occur, and every 4 to 6 months
Chest x-ray	Baseline, as symptoms occur, and every 4 to 6 months
Eye examination	Baseline and as symptoms occur; regular examinations optional
Pulmonary function tests	Baseline and as symptoms occur




FIGURE 1. Chest x-ray showing asymmetric interstitial and alveolar changes with a right basal predominance consistent with amiodarone toxicity.




FIGURE 2. Typical whorled pattern (light gray streaks) of corneal micro-deposits in a patient taking amiodarone.

**Perform liver
function
testing at
baseline and
frequently
thereafter**

darone-induced arrhythmia is low, and the incidence of torsades de pointes is less than 1% when the drug is used as monotherapy.²

Bradycardia from sinus and AV nodal depression is common, sometimes necessitating permanent pacemaker implantation, but it generally reflects a loading dose that is too high and being given too quickly. Intravenous amiodarone may cause hypotension that responds to slowing of the infusion. Outpatient initiation of amiodarone therapy is possible; usually, patients are hospitalized more for arrhythmia management than for observation for amiodarone toxicity.

Hepatic and gastrointestinal effects

An increase in hepatic transaminase of up to 2 to 4 times baseline levels is seen in 15% to 20% of patients during long-term amiodarone therapy.²⁵ The elevation usually takes several months to develop and is generally not dose-dependent. A moderate and persistent increase in alkaline phosphatase has been reported, but changes in bilirubin are unusual. Overt hepatitis is rare (6 of 2210 patients in a large series).⁵ Liver function testing is recommended at baseline and every 4 to 6 months thereafter. The drug should be discontinued for severe transaminase elevation and for evidence of cholestasis or hepatomegaly. Other

side effects include nausea and constipation, which are usually dose-related.

Thyroid effects

Amiodarone, which is about 30% iodine by weight, delivers a large iodine load to the body, and this may produce hypothyroidism and hyperthyroidism. In fact, the iodine load is such that tissue stores of iodine may still be elevated 6 to 9 months after discontinuation of amiodarone treatment.

Because amiodarone blocks the peripheral conversion of thyroxine (T_4) to triiodothyronine (T_3), it often causes elevated levels of serum T_4 and low levels of T_3 . Because T_3 exerts a greater negative feedback effect on thyroid-stimulating hormone (TSH), TSH tends to rise, often returning to normal after a number of months; therefore, this mild elevation of TSH should not be equated with clinical hypothyroidism.

The incidence of clinical hypothyroidism associated with amiodarone is less than 3%, and the incidence of clinical hyperthyroidism is less than 2%.²⁵ Still, more than 50% of patients who receive long-term amiodarone treatment have abnormal thyroid function test results despite absence of clinical symptoms. Amiodarone-induced hypothyroidism—rare after the first 18 months of therapy—responds to thyroid hormone replacement therapy and to lowering the dose of amiodarone. Hyperthyroidism can occur at any time during amiodarone therapy, and clinicians should be aware that it sometimes manifests as a worsening of arrhythmia under treatment. For example, a sinus tachycardia or fast atrial fibrillation may develop, or typically, ventricular tachycardia may become more frequent or sustained due to the hyperthyroidism.

Thyroid function testing is advised at the start of amiodarone treatment, whenever symptoms occur, and at 4- to 6-month intervals thereafter.

The treatment of hyperthyroidism is difficult: radioactive iodine is ineffective, and long-term treatment with antithyroid agents such as methimazole and propylthiouracil has proved disappointing due to high intrathyroidal iodine stores. Addition of perchlorate produces a discharge of intrathyroidal iodine,



but aplastic anemia and nephrotic syndrome are associated side effects. Corticosteroids are somewhat effective, but the benefit is not sustained and the need for high doses is prohibitive. Thyroidectomy or discontinuation of amiodarone therapy may be necessary.²⁶

Other side effects

Ophthalmic effects. Corneal microdeposits (FIGURE 2) are universal during amiodarone therapy and do not in themselves warrant drug discontinuation or routine slit lamp examination. Symptoms of corneal deposits include photophobia, blurred vision, and blue-green halos around objects. Corneal breakdown with cyst formation has occurred from very dense deposits, but this is rare.²⁵ Because of recent reports of optic neuritis associated with amiodarone, the manufacturer now recommends regular ophthalmic examination, including funduscopy and slit lamp examination, for the duration of amiodarone treatment.

Dermatologic effects. Skin photosensitivity is almost universal in patients taking amiodarone. The main treatment is sun-avoidance. Prescribed sunscreens need to filter both ultraviolet A and ultraviolet B radiation. Dose reduction may alleviate symptoms of phototoxicity. Another dermatologic side effect is a blue-gray skin discoloration, seen in 1% to 7% of patients; in this instance, drug discontinuation would be for cosmetic reasons only.²⁵

Neurologic side effects usually consist of tremor, ataxia, and peripheral neuropathy. The treatment is either dose reduction or drug discontinuation.²⁵

Plasma cholesterol levels increase with amiodarone use—a noteworthy effect in the current climate of aggressive lipid lowering for prevention of coronary disease. This increase is independent of the drug's effect on thyroid function. In one study, serum cholesterol levels increased from 197 ± 8 at baseline to 266 ± 31 mg/dL during long-term amiodarone therapy.²⁷

■ INTERACTIONS WITH OTHER DRUGS

The clinician should anticipate certain drug interactions in patients taking amiodarone (TABLE 3). For example, amiodarone has beta-

TABLE 3

Selected concomitant drug effects and dose adjustments

CONCOMITANT DRUG	EFFECT	DOSE ADJUSTMENT
Warfarin	Prothrombin time increased	Decrease by 1/3 to 1/2
Digoxin	Levels increased	Decrease by 1/2
Procainamide	Levels increased	Decrease by 1/2 or stop
Quinidine	Levels increased	Decrease by 1/3 to 1/2 or stop

blocking activity, so combinations of beta-blockers and amiodarone can cause sinus bradycardia or AV nodal blockade. Similarly, some calcium-channel blockers such as verapamil and diltiazem and possibly the newer agent mibefradil may potentiate AV node blockade when used with amiodarone.²⁸ Amiodarone also potentiates the effects of digoxin and warfarin. When initiating amiodarone therapy, the need for concomitant digoxin or warfarin must be reevaluated. If the decision is made to continue both, then the dose of digoxin should be reduced by half and the dose of warfarin by one third to one half.

In addition, amiodarone may act to increase levels of cyclosporine, phenytoin, and methotrexate. Also of note, amiodarone has been used in combination with other antiarrhythmic agents such as mexilitine and flecainide to suppress refractory arrhythmias. Combination therapy such as this may increase the likelihood of torsades de pointes.

■ COST AND DOSAGE

The approach to amiodarone dosage is empirical; the guiding principle is to control arrhythmia with the lowest possible level of toxicity.²⁹ Since serum amiodarone levels correlate poorly with antiarrhythmic efficacy and toxicity, they are useful only as an investigational tool or to monitor compliance and absorption.

Intravenous amiodarone is about 30 times more expensive than the oral prepara-

Skin photosensitivity is almost universal in patients taking amiodarone



tion. The average wholesale price is \$75.65 for a 150-mg vial and \$3.26 for a 200-mg pill. For the urgent termination of refractory arrhythmias, intravenous amiodarone is given as a 150-mg bolus over 10 minutes, followed by an infusion of 1 mg/minute for 6 hours, and a maintenance infusion of 0.5 mg/minute. The other main indication for intravenous amiodarone therapy is in patients unable to tolerate oral amiodarone due to gastrointestinal upset.

Oral amiodarone. Relatively rapid suppression of arrhythmias has been reported with high loading doses of oral amiodarone.³⁰

A recommended oral dosing schedule for refractory ventricular arrhythmias is divided doses of 1200 to 1800 mg/day for 1 to 2 weeks, then 800 mg/day for 2 to 4 weeks, then 600 mg/day for 1 month, and 200 to 400 mg/day thereafter.

For atrial arrhythmias, the loading dose is 600 to 800 mg/day for 4 weeks, then 400 mg/day for 2 to 4 weeks, and 200 mg/day thereafter.³

REFERENCES

- Meyer JB, Amann FW. Additional antianginal efficacy of amiodarone in patients with limiting angina pectoris. *Am Heart J* 1993; 125:996-1001.
- Hohnloser SH, Klingenhoben T, Singh BN. Amiodarone-associated proarrhythmic effects. *Ann Intern Med* 1994; 121:529-535.
- Podrid PJ. Amiodarone: Reevaluation of an old drug. *Ann Intern Med* 1995; 122:689-700.
- Roden DM. Pharmacokinetics of amiodarone: implications for drug therapy. *Am J Cardiol* 1993; 72:45F-50F.
- Mason JW. Amiodarone. *N Engl J Med* 1987; 316:455-466.
- Holt DW, Tucker GT, Jackson PR, Storey GCA. Amiodarone pharmacokinetics. *Am Heart J* 1983; 106:840-847.
- Tielman RG, Gosselink ATM, Crijns H JGM, et al. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. *Am J Cardiol* 1997; 79:53-57.
- Middlekauf HR, Wiener I, Stevenson WG. Low-dose amiodarone for atrial fibrillation. *Am J Cardiol* 1993; 72:75F-81F.
- Daoud EG, Strickberger SA, Ching Man K, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. *N Engl J Med* 1997; 337:1785-1791.
- The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. *N Engl J Med* 1983; 309:331-336.
- Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. *N Engl J Med* 1991; 324:781-788.
- The Cardiac Arrhythmia Suppression Trial 2 Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. *N Engl J Med* 1992; 327:227-233.
- Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Basel Antiarrhythmic Study of Infarct Survival (BASIS). *J Am Coll Cardiol* 1990; 16:1711-1718.
- Cairns JA, Connolly SJ, Roberts R, Gent M, for the CAMI-AT investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. *Lancet* 1997; 349:675-682.
- Julian DG, Camm AJ, Frangin G et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. *Lancet* 1997; 349:667-674.
- Doval HC, Nul DR, Granecelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). *Lancet* 1994; 344:493-498.
- Singh SN, Fletcher RD, Fisher S, et al, for the CHF STAT investigators. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. *N Engl J Med* 1995; 333:77-82.
- Hammill SC, Packer DL. Amiodarone in congestive heart failure: unravelling the GESICA and CHF STAT differences (editorial). *Heart* 1996; 75:6-7.
- Moss AJ, Hall WJ, Cannom DS, et al, for the MADIT investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. *N Engl J Med* 1996; 335:1933-1940.
- Herre JM, Sauve MJ, Malone P, Griffin JC, Helmy I, Langberg JJ. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. *J Am Coll Cardiol* 1989; 13:442-449.
- The CASCADE investigators. Randomised antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). *Am J Cardiol* 1993; 72:70F-74F.
- The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal arrhythmias. *N Engl J Med* 1997; 337:1576-1583.
- Martin WJ 2d, Rosenow EC 3d. Amiodarone pulmonary toxicity. Recognition and pathogenesis. *Chest* 1988; 93:1067-64.
- Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. *Circulation* 1990; 82:51-59.
- Wilson JS, Podrid PJ. Side effects from amiodarone. *Am Heart J* 1991; 121:158-171.
- Harjai KT, Licata AA. Effects of amiodarone on thyroid function. *Ann Intern Med* 1997; 126:63-73.
- Wiersinga WM, Trip MD, van Beeren MH, Plomp TA, Oosting H. An increase in plasma cholesterol independent of thyroid function during long-term amiodarone therapy. *Ann Intern Med* 1991; 114:128-132.
- Marcus FI. Drug interactions with amiodarone. *Am Heart J* 1983; 106:924-930.
- Singh BN. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. *Am J Cardiol* 1996; 78 (suppl 4A):41-53.
- Evans SJL, Myers M, Zaher C, et al. High-dose oral amiodarone loading: electrophysiologic effects and clinical tolerance. *J Am Coll Cardiol* 1992; 19:169-173.

ADDRESS: Bruce L. Wilkoff, MD, Department of Cardiology, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail wilkoffb@cesmtp.ccf.org.